MET and lung carcinoma: Recognizing the clinical significance of MET amplification, leading oncology guidelines, such as the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), have recommended routine testing for MET alterations in patients with lung cancer [15].